Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06023667 · ClinicalTrials.gov registry record · NA
SMART-IBD App Trial
A NA study of Ulcerative Colitis and Crohn Disease, sponsored by Children's Hospital Medical Center, Cincinnati.
- Completed
- Registry status
- NA
- Development phase
- 45
- Enrollment target
- 1
- Study location
NCT06023667: Completed NA study of Ulcerative Colitis and Crohn Disease, sponsored by Children's Hospital Medical Center, Cincinnati.
NCT06023667 is a NA study of Ulcerative Colitis and Crohn Disease that has completed, run by Children's Hospital Medical Center, Cincinnati. The registered enrollment target is 45 participants, below the 2,057-participant average among 122 other Ulcerative Colitis trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06023667, a NA study of Ulcerative Colitis and Crohn Disease, has completed, sponsored by Children's Hospital Medical Center, Cincinnati.
- COMPLETED
- Registry status
- NA
- Development phase
- 45 participants
- Enrollment target
- 1
- Study location
Study Summary
The objective of this trial is to test whether a smartphone app, SMART-IBD, is effective in improving medication adherence and self-management skills in adolescents with IBD. The investigators will conduct a randomized control trial to compare a sample of 20 youth (ages 13-17) with IBD using an app that has educational content and medication reminders to 20 youth in an attention control group. The length of the intervention will include one month of baseline adherence data collection, one month of intervention, and one month of post-treatment adherence data collection.
Primary Outcome
Medication adherence will be measured using electronic monitoring of medications indicated being taken in the SMART-IBD app
Conditions Studied
Interventions
- BEHAVIORAL SMART-IBD
Study Locations (1)
Ohio
- Cincinnati Children's Hospital Medical Center - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2022-12-14 |
| Est. Completion | 2023-12-28 |
| Phase | NA |
What the finished NCT06023667 record still lists
NCT06023667 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 45 participants, a relatively small participant target, below the 2,057-participant average among 122 other Ulcerative Colitis trials with a reported enrollment target (98% lower).
The record links to 4 conditions, with Ulcerative Colitis appearing as the primary indexed condition, and to 1 intervention - of which SMART-IBD is the first listed.
NCT06023667 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT06023667 about?
NCT06023667 is a clinical study titled "SMART-IBD App Trial". The objective of this trial is to test whether a smartphone app, SMART-IBD, is effective in improving medication adherence and self-management skills in adolescents with IBD. The investigators will conduct a randomized control trial to compare a sample of 20 youth (ages 13-17) with IBD using an app ...
What is the current status of trial NCT06023667?
This trial is currently completed. It is a NA study. The enrollment target is 45 participants. The study started on 2022-12-14. Estimated completion is 2023-12-28.
What conditions does trial NCT06023667 study?
This clinical trial studies the following conditions: Ulcerative Colitis, Crohn Disease, Inflammatory Bowel Diseases, IBD.
What interventions are being tested in trial NCT06023667?
The interventions under investigation include: SMART-IBD (BEHAVIORAL).
Who is sponsoring clinical trial NCT06023667?
This trial is sponsored by Children's Hospital Medical Center, Cincinnati, which has 571 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06023667 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ulcerative Colitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06023667's enrollment target sits among peer trials
45 90th of 122 higher than 32 of 122 other Ulcerative Colitis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Ulcerative Colitis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Treat-to-Target of Endoscopic Remission in Patients With IBD in Symptomatic Remission
RECRUITING · NA
-
A Study of Endoscopic Sleeve Gastroplasty for Obesity in Ulcerative Colitis
RECRUITING · NA
-
Nicotinamide Riboside in Ulcerative Colitis
RECRUITING · NA
-
Fermented Food-Supplemented Diet in Ulcerative Colitis
RECRUITING · NA
-
Impact of Prebiotics in Ulcerative Colitis
RECRUITING · NA
-
Tailored Anti-Inflammatory (A-I) Diet for Americans With Ulcerative Colitis (UC)
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00804154 · 45 participants · Phase 1
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
- NCT01851694 · 45 participants · NA
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
- NCT02896335 · 45 participants · Phase 2
Palbociclib and Pembrolizumab In Central Nervous System Metastases
- NCT03454035 · 45 participants · Phase 1
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI